同: Ambisome

WordNet

the 2nd letter of the Roman alphabet (同)b
the blood group whose red cells carry the B antigen (同)type_B, group B
having characteristics of both an acid and a base and capable of reacting as either (同)amphiprotic
an antibiotic and antifungal agent

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2015/11/24 07:33:01」(JST)

wiki en

Amphotericin B is an antifungal drug often used intravenously for serious systemic fungal infections and is the only effective treatment for some fungal infections.^[1]

Common side effects include a reaction of fever, shaking chills, headaches and low blood pressure soon after it is infused, as well as kidney and electrolyte problems.^[1] Allergic symptoms including anaphylaxis may occur.^[1]

It was originally extracted from Streptomyces nodosus, a filamentous bacterium, in 1955, at the Squibb Institute for Medical Research. Its name originates from the chemical's amphoteric properties. It is on the World Health Organization's List of Essential Medicines, the most important medications needed in a basic health system.^[2]

It is of the polyene class. Currently, the drug is available in many forms. Either "conventionally" complexed with sodium deoxycholate (ABD), as a cholesteryl sulfate complex (ABCD), as a lipid complex (ABLC), and as a liposomal formulation (LAMB). The latter formulations have been developed to improve tolerability and decrease toxicity, but may show considerably different pharmacokinetic characteristics compared to conventional amphotericin B.^[3]

1 Medical uses
- 1.1 Antifungal
- 1.2 Antiprotozoal
- 1.3 Spectrum of susceptibility
2 Route of administration
- 2.1 Intravenous
  - 2.1.1 Deoxycholate
  - 2.1.2 Liposomal formulations
  - 2.1.3 Lipid complex formulations
- 2.2 Oral preparations
3 Side effects
4 Interactions
5 Mechanism of action
6 Mechanism of toxicity
7 Biosynthesis
8 History
9 Society and culture
- 9.1 Brand names
10 References
11 External links

Medical uses

Antifungal

One of the main uses of amphotericin B is treating a wide range of systemic fungal infections. Due to its extensive side effects, it is often reserved for severe infections in critically ill, or immunocompromised patients. It is considered first line therapy for invasive mucormycosis infections, cryptococcal meningitis, and certain aspergillus and candidal infections.^[4]^[5]

Antiprotozoal

Amphotericin B is often used in otherwise-untreatable protozoan infections such as visceral leishmaniasis^[6] and primary amoebic meningoencephalitis.^[7]

Spectrum of susceptibility

The following table shows the Amphotericin B susceptibility for a selection of medically important fungi.

Species	Amphotericin B MIC breakpoint (mg/L)
Aspergillus fumigatus	1^[8]
Aspergillus terreus	Resistant^[8]^[9]
Candida albicans	1^[8]
Candida krusei	1^[8]
Candida glabrata	1^[8]
Candida lusitaniae	Intrinsically resistant^[9]
Cryptococcus neoformans	2^[10]
Fusarium oxysporum	2^[10]

Route of administration

Intravenous

Deoxycholate

Amphotericin B alone is insoluble in normal saline at a pH of 7. The original formulation used sodium deoxycholate to improve solubility.^[3] Amphotericin B deoxycholate (ABD) is administered IV, though with frequent adverse effects as detailed in the side effects section.^[11] As the original formulation of amphotericin, it is often referred to as "conventional" amphotericin.^[12]

Liposomal formulations

In order to improve the tolerability of amphotericin and reduce toxicity, several lipid formulations have been developed.^[3]

From studies, it appears that liposomal amphotericin B preparations exhibit fewer side effects, while having similar efficacy. Various preparations have recently been introduced. All of these are more expensive than plain amphotericin B.

AmBisome (LAMB) is a liposomal formulation of amphotericin B for injection, developed by NeXstar Pharmaceuticals (acquired by Gilead Sciences in 1999). It was approved by the FDA in 1997.^[13] It is marketed by Gilead in Europe and licensed to Astellas Pharma (formerly Fujisawa Pharmaceuticals) for marketing in the USA, and Sumitomo Pharmaceuticals in Japan. It consists of a mixture of phosphatidylcholine, cholesterol and distearoyl phosphatidylglycerol that in aqueous media they spontaneously arrange into unilamellar vesicles that contain amphotericin B.^[3]^[14]

Liposomal formulations have been primarily used as it has been found to have less renal toxicity than deoxycholate.^[15] Guidelines also recommend the use of LAMB for CNS fungal infections due to better pharmacokinetics and CNS penetration but do note that this is based only on animal models.^[16]^[17]

Fungisome^[18] is a generic liposomal complex of amphotericin B. It is marketed by Lifecare Innovations of India.

Lipid complex formulations

Amphotec (ABCD) and Abelcet (ABLC) are lipid complex preparations. Abelcet was approved by the FDA in 1995.^[19] It consists of amphotericin B and two lipids in a 1:1 ratio that form large ribbon-like structures.^[3] Amphotec is a complex of amphotericin and sodium cholesteryl sulfate in a 1:1 ratio. Two molecules of each form a tetramer that aggregate into spiral arms on a disk-like complex.^[14] It was approved by the FDA in 1996.^[20] Neither of these are true unilamellar liposomes like ambisome.

Oral preparations

A major barrier to the use of amphotericin in resource-poor settings is that it must be given intravenously (except for topical applications). An oral preparation exists, but is not commercially available.^[21] The amphipathic nature of amphotericin along with its low solubility and permeability has posed major hurdles for oral administration given its low bioavailability. In the past it had been used for fungal infections of the surface of the GI tract such as thrush, but has been replaced by other antifungals such as nystatin and fluconazole.^[22]

However, recently novel nanoparticulate drug delivery systems such as AmbiOnp,^[23] nanosuspensions, lipid-based drug delivery systems including cochleates, self-emulsifying drug delivery systems,^[24] solid lipid nanoparticles^[25] and polymeric nanoparticles^[26]—such as Amphotericin B in pegylated polylactide coglycolide copolymer nanoparticles^[27]—have demonstrated potential for oral formulation of amphotericin B.^[28]

Side effects

Amphotericin B is well known for its severe and potentially lethal side effects. Very often, a serious acute reaction after the infusion (1 to 3 hours later) is noted, consisting of high fever, shaking chills (leading to the medical slang term "shake and bake"),^[29] hypotension, anorexia, nausea, vomiting, headache, dyspnea and tachypnea, drowsiness, and generalized weakness. This reaction sometimes subsides with later applications of the drug, and may in part be due to histamine liberation. An increase in prostaglandin synthesis may also play a role. This nearly universal febrile response necessitates a critical (and diagnostically difficult) professional determination as to whether the onset of high fever is a novel symptom of a fast-progressing disease, or merely the effect of the drug. To decrease the likelihood and severity of the symptoms, initial doses should be low, and increased slowly. Paracetamol, pethidine, diphenhydramine, and hydrocortisone have all been used to treat or prevent the syndrome, but the prophylactic use of these drugs is often limited by the patient's condition.

Intravenously administered amphotericin B in therapeutic doses has also been associated with multiple organ damage. Kidney damage is a frequently reported side effect, and can be severe and/or irreversible. Less kidney toxicity has been reported with liposomal formulations such as AmBisome) and it has become preferred in patients with preexisting renal injury.^[30]^[31] The integrity of the liposome is disrupted when it binds to the fungal cell wall, but is not affected by the mammalian cell membrane,^[32] so the association with liposomes decreases the exposure of the kidneys to amphotericin B, which explains its less nephrotoxic effects.^[33]

In addition, electrolyte imbalances such as hypokalemia and hypomagnesemia are also common.^[34] In the liver, increased liver enzymes and hepatotoxicity (up to and including fulminant liver failure) are common. In the circulatory system, several forms of anemia and other blood dyscrasias (leukopenia, thrombopenia), serious cardiac arrhythmias (including ventricular fibrillation), and even frank cardiac failure have been reported. Skin reactions, including serious forms, are also possible.

Interactions

Flucytosine: Toxicity of flucytosine is increased and allows a lower dose of amphotericin B. Amphotericin B may also facilitate entry of flucystosine into the fungal cell by interfering with the permeability of the fungal cell membrane.
Diuretics or cisplatin: Increased renal toxicity and increased risk of hypokalemia
Corticosteroids: Increased risk of hypokalemia
Cytostatic drugs: Increased risk of kidney damage, hypotension, and bronchospasms
Other nephrotoxic drugs (such as aminoglycosides): Increased risk of serious renal damage
Foscarnet, ganciclovir, tenofovir, adefovir: Risk of hematological and renal side effects of amphotericin B are increased
Transfusion of leukocytes: Risk of pulmonal (lung) damage occurs, space the intervals between the application of amphotericin B and the transfusion, and monitor pulmonary function

Mechanism of action

As with other polyene antifungals, amphotericin B binds with ergosterol, a component of fungal cell membranes, forming a transmembrane channel that leads to monovalent ion (K⁺, Na⁺, H⁺ and Cl⁻) leakage, which is the primary effect leading to fungal cell death. Researchers have found evidence that pore formation is not the only mechanism responsible for cell death.^[35]^[36] By an unknown mechanism, amphotericin B also causes oxidative stress within the fungal cell and the addition of free radical scavengers or induction of antioxidant enzymes in pathogens can lead to amphotericin resistance in species such as scedosporium prolificans without having to effect cell wall ergosterol.^[37]^[38]

Two amphotericins, amphotericin A and amphotericin B, are known, but only B is used clinically, because it is significantly more active in vivo. Amphotericin A is almost identical to amphotericin B (having a double C=C bond between the 27th and 28th carbons), but has little antifungal activity.^[39]

Mechanism of toxicity

Mammalian and fungal membranes both contain sterols, a primary membrane target for amphotericin B. Because mammalian and fungal membranes are similar in structure and composition, this is one mechanism by which amphotericin B causes cellular toxicity. Amphotericin B molecules can form pores in the host membrane as well as the fungal membrane. This impairment in membrane barrier function can have lethal effects.^[36]^[40]^[41] Bacteria are not affected as their cell membranes do not contain sterols.

Amphotericin administration is limited by infusion-related toxicity. This is thought to result from innate immune production of proinflammatory cytokines.^[40]^[42]

Biosynthesis

The natural route to synthesis includes polyketide synthase components.^[43] The carbon chains of Amphotericin B are assembled from sixteen ‘C2’ acetate and three ‘C3’propionate units by polyketide synthases (PKSs). ^[44] Polyketide biosynthesis begins with the decarboxylative condensation of a dicarboxylic acid extender unit with a starter acyl unit to form a β-ketoacyl intermediate. The growing chain is constructed by a series of Claisen reactions. Within each module, the extender units are loaded onto the current ACP domain by acetyl transferase (AT). The ACP-bound elongation group reacts in a Claisen condensation with the KS-bound polyketide chain. Ketoreductase (KR), dehydratase (DH) and enoyl reductase (ER) enzymes may also be present to form alcohol, double bonds or single bonds. ^[45] After cyclisation, the macrolactone core undergoes further modification by hydroxylation, methylation and glycosylation. The order of these processes is unknown.

History

It was originally extracted from Streptomyces nodosus, a filamentous bacterium, in 1955, at the Squibb Institute for Medical Research from cultures of an undescribed streptomycete isolated from the soil collected in the Orinoco River region of Venezuela.^[39] Two antifungal substances were isolated from the soil culture, Amphotericin A and Amphotericin B, but B had better antifungal activity. For decades it remained it the only effective therapy for invasive fungal disease until the development of the azole antifungals in the early 1980s.^[11]

Its complete stereo structure was determined in 1970 by an X-ray structure of the N-iodoacetyl derivative. ^[46] The first synthesis of the compound's naturally occurring enantiomeric form was achieved in 1988. ^[47]

Society and culture

Brand names

Fungilin, Fungizone, Abelcet, AmBisome, Fungisome, Amphocil, Amphotec

References

^ ^a ^b ^c "Amphotericin B". The American Society of Health-System Pharmacists. Retrieved Jan 1, 2015.
^ "WHO Model List of EssentialMedicines" (PDF). World Health Organization. October 2013. Retrieved 22 April 2014.
^ ^a ^b ^c ^d ^e Hamill, Richard J. (2013-06-01). "Amphotericin B Formulations: A Comparative Review of Efficacy and Toxicity". Drugs 73 (9): 919–934. doi:10.1007/s40265-013-0069-4. ISSN 0012-6667.
^ Drugs Active against Fungi, Pneumocystis, and Microsporidia. pp. 479–494.e4. ISBN 978-1-4557-4801-3.
^ Moen, Marit D.; Lyseng-Williamson, Katherine A.; Scott, Lesley J. (2012-09-17). "Liposomal Amphotericin B". Drugs 69 (3): 361–392. doi:10.2165/00003495-200969030-00010. ISSN 0012-6667.
^ den Boer, Margriet; Davidson, Robert N. (2006-04-01). "Treatment options for visceral leishmaniasis". Expert Review of Anti-Infective Therapy 4 (2): 187–197. doi:10.1586/14787210.4.2.187. ISSN 1744-8336. PMID 16597201.
^ Grace, Eddie; Asbill, Scott; Virga, Kris (November 2015). "Naegleria fowleri: Pathogenesis, Diagnosis, and Treatment Options". Antimicrobial Agents and Chemotherapy 59 (11): 6677–6681. doi:10.1128/AAC.01293-15. PMID 26259797.
^ ^a ^b ^c ^d ^e "European Committee on Antimicrobial Susceptibility Testing: Antifungal Agents, Breakpoint tables for interpretation of MICs" (PDF). 11/16/2015. Retrieved 11/17/2015. Check date values in: |access-date=, |date= (help)
^ ^a ^b Hamill, Richard J. (2013-06-01). "Amphotericin B Formulations: A Comparative Review of Efficacy and Toxicity". Drugs 73 (9): 919–934. doi:10.1007/s40265-013-0069-4. ISSN 0012-6667.
^ ^a ^b "Index | The Antimicrobial Index Knowledgebase - TOKU-E". antibiotics.toku-e.com. Retrieved 2015-11-17.
^ ^a ^b Maertens, J. A. (2004-03-01). "History of the development of azole derivatives". Clinical Microbiology and Infection 10: 1–10. doi:10.1111/j.1470-9465.2004.00841.x. ISSN 1469-0691.
^ "Comparison of Fungizone, Amphotec, AmBisome, and Abelcet for Treatment of Systemic Murine Cryptococcosis". Antimicrobial Agents and Chemotherapy. April 1998. PMID 9559804.
^ "Drug Approval Package". www.accessdata.fda.gov. Retrieved 2015-11-03.
^ ^a ^b Slain, Douglas (1999-03-01). "Lipid-Based Amphotericin B for the Treatment of Fungal Infections". Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 19 (3): 306–323. doi:10.1592/phco.19.4.306.30934. ISSN 1875-9114.
^ Mistro, Sóstenes; Maciel, Isis de M.; Menezes, Rouseli G. de; Maia, Zuinara P.; Schooley, Robert T.; Badaró, Roberto (2012-06-15). "Does Lipid Emulsion Reduce Amphotericin B Nephrotoxicity? A Systematic Review and Meta-analysis". Clinical Infectious Diseases 54 (12): 1774–1777. doi:10.1093/cid/cis290. ISSN 1058-4838. PMID 22491505.
^ Pappas, Peter G.; Kauffman, Carol A.; Andes, David; Benjamin, Daniel K.; Calandra, Thierry F.; Edwards, John E.; Filler, Scott G.; Fisher, John F.; Kullberg, Bart-Jan (2009-03-01). "Clinical Practice Guidelines for the Management Candidiasis: 2009 Update by the Infectious Diseases Society of America". Clinical Infectious Diseases 48 (5): 503–535. doi:10.1086/596757. ISSN 1058-4838. PMID 19191635.
^ Groll, A. H.; Giri, N.; Petraitis, V.; Petraitiene, R.; Candelario, M.; Bacher, J. S.; Piscitelli, S. C.; Walsh, T. J. (2000-07-01). "Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system". The Journal of Infectious Diseases 182 (1): 274–282. doi:10.1086/315643. ISSN 0022-1899. PMID 10882607.
^ "Untitled Document". www.fungisome.com. Retrieved 2015-11-03.
^ "Drugs@FDA: FDA Approved Drug Products". www.accessdata.fda.gov. Retrieved 2015-11-03.
^ "Drugs@FDA: FDA Approved Drug Products". www.accessdata.fda.gov. Retrieved 2015-11-03.
^ Wasan KM, Wasan EK, Gershkovich P; et al. (2009). "Highly Effective oral amphotericin B formulation against murine visceral leishmaniasis". J Infect Dis 200 (3): 357–360. doi:10.1086/600105. PMID 19545212.
^ Pappas, Peter G.; Kauffman, Carol A.; Andes, David; Benjamin, Daniel K.; Calandra, Thierry F.; Edwards, John E.; Filler, Scott G.; Fisher, John F.; Kullberg, Bart-Jan (2009-03-01). "Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America". Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 48 (5): 503–535. doi:10.1086/596757. ISSN 1537-6591. PMID 19191635.
^ Patel, Pratikkumar A., and Vandana B. Patravale. "AmbiOnp: solid lipid nanoparticles of amphotericin B for oral administration." Journal of Biomedical Nanotechnology 7.5 (2011): 632-639.
^ Wasan EK, Bartlett K, Gershkovich P, Sivak O, Banno B, Wong Z, Gagnon J, Gates B, Leon CG, Wasan KM. Development and characterization of oral lipid-based amphotericin B formulations with enhanced drug solubility, stability and antifungal activity in rats infected with Aspergillus fumigatus or Candida albicans. International Journal of Pharmaceutics. 2009; 372(1-2):76-84
^ Patel PA, Patravale,VB. AmbiOnp: solid lipid nanoparticles of amphotericin B for oral administration. Journal of Biomedical Nanotechnology.2011; 7(5):632-639
^ Italia JL, Yahya MM, Singh D. Biodegradable nanoparticles improve oral Bioavailability of Amphotericin B and Show Reduced Nephrotoxicity Compared to Intravenous Fungizone®. Pharmaceutical Research. 2009; 26 (6): 1324 -1331
^ AL-Quadeib, Bushra T.; Radwan, Mahasen A.; Siller, Lidija; Horrocks, Benjamin; Wright, Matthew C. (2015-07-01). "Stealth Amphotericin B nanoparticles for oral drug delivery: In vitro optimization". Saudi Pharmaceutical Journal 23 (3): 290–302. doi:10.1016/j.jsps.2014.11.004. PMC 4475820. PMID 26106277.
^ Patel PA, Fernandes CB, Pol AS, Patravale VB. Oral Amphotericin B: Challenges and avenues. Int. J. Pharm. Biosci. Technol. 2013;1(1):1–9
^ MedBullets.Org - Amphotericin B
^ Walsh, Thomas J.; Finberg, Robert W.; Arndt, Carola; Hiemenz, John; Schwartz, Cindy; Bodensteiner, David; Pappas, Peter; Seibel, Nita; Greenberg, Richard N. (1999-03-11). "Liposomal Amphotericin B for Empirical Therapy in Patients with Persistent Fever and Neutropenia". New England Journal of Medicine 340 (10): 764–771. doi:10.1056/NEJM199903113401004. ISSN 0028-4793. PMID 10072411.
^ Perfect, John R.; Dismukes, William E.; Dromer, Francoise; Goldman, David L.; Graybill, John R.; Hamill, Richard J.; Harrison, Thomas S.; Larsen, Robert A.; Lortholary, Olivier (2010-02-01). "Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America". Clinical Infectious Diseases 50 (3): 291–322. doi:10.1086/649858. ISSN 1058-4838. PMID 20047480.
^ Jill Adler-Moore,* and Richard T. liposomal formulation, structure, mechanism of action and pre-clinical experience. Journal of Antimicrobial Chemotherapy (2002) 49, 21–30
^ J. Czub, M. Baginski. Amphotericin B and Its New Derivatives Mode of action. Department of pharmaceutical Technology and Biochemistry. Faculty of Chemistry, Gdnsk University of Technology. 2009, 10-459-469.
^ Zietse, R.; Zoutendijk, R.; Hoorn, E. J. "Fluid, electrolyte and acid–base disorders associated with antibiotic therapy". Nature Reviews Nephrology 5 (4): 193–202. doi:10.1038/nrneph.2009.17.
^ Angewandte Chemie Int. Ed. Engl. 2004^{[page needed]}
^ ^a ^b Baginski, M.; Czub, J. (2009). "Amphotericin B and Its New Derivatives–Mode of Action". Current Drug Metabolism 10 (5): 459–69. doi:10.2174/138920009788898019. PMID 19689243.
^ Mesa-Arango, Ana Cecilia; Scorzoni, Liliana; Zaragoza, Oscar (2012-01-01). "It only takes one to do many jobs: Amphotericin B as antifungal and immunomodulatory drug". Fungi and Their Interactions 3: 286. doi:10.3389/fmicb.2012.00286. PMC 3441194. PMID 23024638.
^ O'Keeffe, Joseph; Doyle, Sean; Kavanagh, Kevin (2003-12-01). "Exposure of the yeast Candida albicans to the anti-neoplastic agent adriamycin increases the tolerance to amphotericin B". Journal of Pharmacy and Pharmacology 55 (12): 1629–1633. doi:10.1211/0022357022359. ISSN 2042-7158.
^ ^a ^b Dutcher, James D. (1968-10-01). "THe discovery and development of amphotericin b". Chest 54 (Supplement_1): 296–298. doi:10.1378/chest.54.Supplement_1.296. ISSN 0012-3692.
^ ^a ^b Laniado-Laborin R. and Cabrales-Vargas MN. Amphotericin B: side effects and toxicity. Revista Iberoamericana de Micologia. (2009): 223–7.
^ Pfizer. Amphocin. Accessed at http://www.pfizer.com/files/products/uspi_amphocin.pdf on Feb 18 2010.
^ Drew, R. Pharmacology of amphotericin B. Uptodate. Sep 2009. Accessed at http://www.utdol.com/online/content/topic.do?topicKey=antibiot/4619&selectedTitle=2~150&source=search_result on Feb 18 2010.
^ Khan N, Rawlings B, Caffrey P (2011-01-26). "A labile point in mutant amphotericin polyketide synthases". Biotechnol Lett. 33 (6): 1121–6. doi:10.1007/s10529-011-0538-3. PMID 21267757.
^ McNamara, Carmel M.; Box, Stephen; Crawforth, James M.; Hickman, Benjamin S.; Norwood, Timothy J. (1998-01-01). "Biosynthesis of amphotericin B". Journal of the Chemical Society, Perkin Transactions 1: 83–88. doi:10.1039/A704545J. |access-date= requires |url= (help)
^ Caffrey, Patrick; Lynch, Susan; Flood, Elizabeth; Finnan, Shirley; Oliynyk, Markiyan (2001). "Amphotericin biosynthesis in Streptomyces nodosus: deductions from analysis of polyketide synthase and late genes". Chemistry & biology 8 (7): 713–723. doi:10.1016/S1074-5521(01)00046-1. |access-date= requires |url= (help)
^ McNamara, Carmel M.; Box, Stephen; Crawforth, James M.; Hickman, Benjamin S.; Norwood, Timothy J.; Rawlings, Bernard J. "Biosynthesis of amphotericin B". Journal of the Chemical Society, Perkin Transactions 1 (1): 83–88. doi:10.1039/a704545j.
^ Nicolaou, K. C.; Daines, R. A.; Chakraborty, T. K.; Ogawa, Y. (1987-04-01). "Total synthesis of amphotericin B". Journal of the American Chemical Society 109 (9): 2821–2822. doi:10.1021/ja00243a043. ISSN 0002-7863.

External links

AmBisome web site run by Astella Pharma
"Special issue". Journal of Postgraduate Medicine 51 (Suppl). 2005.
Review Article: Oral Amphotericin B:Challenges and avenues

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. アムホテリシンBの薬理 pharmacology of amphotericin b
2. アムホテシリンBによる腎毒性 amphotericin b nephrotoxicity
3. 侵襲性アスペルギルス症の治療および予防 treatment and prevention of invasive aspergillosis
4. HIV感染患者におけるクリプトコッカス-ネオフォルマン髄膜脳炎の治療 treatment of cryptococcus neoformans meningoencephalitis in hiv infected patients
5. 内臓リーシュマニア症の治療 treatment of visceral leishmaniasis

English Journal

Cutaneous leishmaniasis caused by Leishmania infantum in Southern Israel.

Ben-Shimol S, Sagi O, Horev A, Avni YS, Ziv M, Riesenberg K.
Acta parasitologica.Acta Parasitol.2016 Dec 1;61(4):855-858. doi: 10.1515/ap-2016-0118.
Cutaneous leishmaniasis (CL) caused by Leishmania major is common in southern Israel, while Leishmania infantum (sub-strain of L. donovani, causing zoonotic visceral leishmaniasis) infections were rarely reported in Israel and only in other regions. We report the first case of L. infantum infection
PMID 27787222

Confusion between Two Amphotericin B Formulations Leading to a Paediatric Rehospitalisation.

Fleury M1,2, Fonzo-Christe C3, Normand C4, Bonnabry P5,3.
Drug safety - case reports.Drug Saf Case Rep.2016 Dec;3(1):4.
A heavily immunosuppressed, 43-kg, 9-year-old patient was recovering from a bone marrow transplant. Primary prophylaxis against invasive fungal infections was liposomal amphotericin B (AmBisome®, 2.3 mg/kg [100 mg] two times per week). Once home, following a first amphotericin B infusion, he presen
PMID 27747684

Detection of Circulating Mucorales DNA in Critically Ill Burn Patients: Preliminary Report of a Screening Strategy for Early Diagnosis and Treatment.

Legrand M1,2,3, Gits-Muselli M4, Boutin L1, Garcia-Hermoso D5,6, Maurel V1, Soussi S1, Benyamina M1, Ferry A1, Chaussard M1, Hamane S4, Denis B7, Touratier S8, Guigue N4, Fréalle E9, Jeanne M10, Shaal JV11, Soler C12, Mimoun M2,13, Chaouat M2,13, Lafaurie M7, Mebazaa A1,2,3, Bretagne S2,4,5,6, Alanio A2,4,5,6.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.Clin Infect Dis.2016 Nov 15;63(10):1312-1317. Epub 2016 Aug 17.
BACKGROUND: Invasive wound mucormycosis (IWM) is associated with an extremely poor outcome among critically ill burn patients. We describe the detection of circulating Mucorales DNA (cmDNA) for the early diagnosis of IWM in those patients and report the potential value of detecting cmDNA for trea
PMID 27535951

Japanese Journal

ERRATUM - Intravenous liposomal amphotericin B versus voriconazole for chronic pulmonary aspergillosis: a multicenter trial in Japan

Acta medica Nagasakiensia 62(1), 43-43, 2018-10
NAID 120006532051

A Case of Conjunctival Ulcer and Uveitis Caused by <i>Acrophialophora</i> Sp. in an Immunocompromised Patient: a Case Report and Riterature Review

Japanese Journal of Infectious Diseases 71(6), 467-469, 2018
NAID 130007520838

早期の想定が功を奏した急性骨髄性白血病の骨髄移植後に発症した播種性皮膚ムコール感染症例

日本小児血液・がん学会雑誌 55(3), 298-303, 2018
NAID 130007500957

「ambisome」

Amphotericin B
Systematic (IUPAC) name
	(1R,3S,5R,6R,9R, 11R,15S,16R,17R,18S,19E,21E, 23E,25E,27E,29E,31E,33R,35S,36R,37S)- 33-[(3-amino- 3,6-dideoxy- β-D-mannopyranosyl)oxy]- 1,3,5,6,9,11,17,37-octahydroxy- 15,16,18-trimethyl- 13-oxo- 14,39-dioxabicyclo [33.3.1] nonatriaconta- 19,21,23,25,27,29,31-heptaene- 36-carboxylic acid
Clinical data
Trade names	Fungizone
AHFS/Drugs.com	monograph
Pregnancy; category	US: B (No risk in non-human studies); ;
Legal status	Rx-only, hospitalization recommended.;
Routes of; administration	I.V. (slow infusion only) topical
Pharmacokinetic data
Bioavailability	100% (IV)
Metabolism	renal
Biological half-life	initial phase : 24 hours,; second phase : approx. 15 days
Excretion	40% found in urine after single cumulated over several days; biliar excretion also important
Identifiers
CAS Number	1397-89-3
ATC code	A01AB04 A07AA07, G01AA03, J02AA01
PubChem	CID: 14956
DrugBank	DB00681
ChemSpider	10237579
KEGG	D00203
ChEBI	CHEBI:2682
ChEMBL	CHEMBL267345
NIAID ChemDB	000096
Chemical data
Formula	C47H73NO17
Molecular mass	923.49
	SMILES O=C(O)[C@@H]3[C@@H](O)C[C@@]2(O)C[C@@H](O)C[C@@H](O)[C@H](O)CC[C@@H](O)C[C@@H](O)CC(=O)O[C@@H](C)[C@H](C)[C@H](O)[C@@H](C)C=CC=CC=CC=CC=CC=CC=C[C@H](O[C@@H]1O[C@H](C)[C@@H](O)[C@H](N)[C@@H]1O)C[C@@H]3O2 ;
	InChI InChI=1S/C47H73NO17/c1-27-17-15-13-11-9-7-5-6-8-10-12-14-16-18-34(64-46-44(58)41(48)43(57)30(4)63-46)24-38-40(45(59)60)37(54)26-47(61,65-38)25-33(51)22-36(53)35(52)20-19-31(49)21-32(50)23-39(55)62-29(3)28(2)42(27)56/h5-18,27-38,40-44,46,49-54,56-58,61H,19-26,48H2,1-4H3,(H,59,60)/b6-5+,9-7+,10-8+,13-11+,14-12+,17-15+,18-16+/t27-,28-,29-,30+,31+,32+,33-,34-,35+,36+,37-,38-,40+,41-,42+,43+,44-,46-,47+/m0/s1 ; Key:APKFDSVGJQXUKY-INPOYWNPSA-N ;
(what is this?) (verify)

　　[★]

同: liposomal amphotericin B

「B」

　　[★]

気管分岐部下緑
補体のalternative pathwayに関わる蛋白質

Mg2+存在下でC3, B, Dが反応してC3bBbとなり、これがC3転換酵素(C3bBb)あるいはC5転換酵素(C3bBb3b)を形成する。これらはP(properdin)と結合して活性化し、それぞれC3、C5を活性化する

「amphotericin」

　　[★]

アンホテリシン、アムホテリシン

関: amphotericin B

「liposomal」

　　[★]

リ・ソームの

関: liposome

「amphoteric」

　　[★]

両性の

関: both sexes

[AHFS2015-1] "Amphotericin B". The American Society of Health-System Pharmacists. Retrieved Jan 1, 2015.

[2] "WHO Model List of EssentialMedicines" (PDF). World Health Organization. October 2013. Retrieved 22 April 2014.

[:0-3] Hamill, Richard J. (2013-06-01). "Amphotericin B Formulations: A Comparative Review of Efficacy and Toxicity". Drugs 73 (9): 919–934. doi:10.1007/s40265-013-0069-4. ISSN 0012-6667.

[4] Drugs Active against Fungi, Pneumocystis, and Microsporidia. pp. 479–494.e4. ISBN 978-1-4557-4801-3.

[5] Moen, Marit D.; Lyseng-Williamson, Katherine A.; Scott, Lesley J. (2012-09-17). "Liposomal Amphotericin B". Drugs 69 (3): 361–392. doi:10.2165/00003495-200969030-00010. ISSN 0012-6667.

[6] Boer, Margriet; Davidson, Robert N. (2006-04-01). "Treatment options for visceral leishmaniasis". Expert Review of Anti-Infective Therapy 4 (2): 187–197. doi:10.1586/14787210.4.2.187. ISSN 1744-8336. PMID 16597201.

[7] Grace, Eddie; Asbill, Scott; Virga, Kris (November 2015). "Naegleria fowleri: Pathogenesis, Diagnosis, and Treatment Options". Antimicrobial Agents and Chemotherapy 59 (11): 6677–6681. doi:10.1128/AAC.01293-15. PMID 26259797.

[:4-8] "European Committee on Antimicrobial Susceptibility Testing: Antifungal Agents, Breakpoint tables for interpretation of MICs" (PDF). 11/16/2015. Retrieved 11/17/2015. Check date values in: |access-date=, |date= (help)

[:5-9] Hamill, Richard J. (2013-06-01). "Amphotericin B Formulations: A Comparative Review of Efficacy and Toxicity". Drugs 73 (9): 919–934. doi:10.1007/s40265-013-0069-4. ISSN 0012-6667.

[:6-10] "Index | The Antimicrobial Index Knowledgebase - TOKU-E". antibiotics.toku-e.com. Retrieved 2015-11-17.

[:1-11] Maertens, J. A. (2004-03-01). "History of the development of azole derivatives". Clinical Microbiology and Infection 10: 1–10. doi:10.1111/j.1470-9465.2004.00841.x. ISSN 1469-0691.

[12] "Comparison of Fungizone, Amphotec, AmBisome, and Abelcet for Treatment of Systemic Murine Cryptococcosis". Antimicrobial Agents and Chemotherapy. April 1998. PMID 9559804.

[13] "Drug Approval Package". www.accessdata.fda.gov. Retrieved 2015-11-03.

[:2-14] Slain, Douglas (1999-03-01). "Lipid-Based Amphotericin B for the Treatment of Fungal Infections". Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 19 (3): 306–323. doi:10.1592/phco.19.4.306.30934. ISSN 1875-9114.

[15] Mistro, Sóstenes; Maciel, Isis de M.; Menezes, Rouseli G. de; Maia, Zuinara P.; Schooley, Robert T.; Badaró, Roberto (2012-06-15). "Does Lipid Emulsion Reduce Amphotericin B Nephrotoxicity? A Systematic Review and Meta-analysis". Clinical Infectious Diseases 54 (12): 1774–1777. doi:10.1093/cid/cis290. ISSN 1058-4838. PMID 22491505.

[16] Pappas, Peter G.; Kauffman, Carol A.; Andes, David; Benjamin, Daniel K.; Calandra, Thierry F.; Edwards, John E.; Filler, Scott G.; Fisher, John F.; Kullberg, Bart-Jan (2009-03-01). "Clinical Practice Guidelines for the Management Candidiasis: 2009 Update by the Infectious Diseases Society of America". Clinical Infectious Diseases 48 (5): 503–535. doi:10.1086/596757. ISSN 1058-4838. PMID 19191635.

[17] Groll, A. H.; Giri, N.; Petraitis, V.; Petraitiene, R.; Candelario, M.; Bacher, J. S.; Piscitelli, S. C.; Walsh, T. J. (2000-07-01). "Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system". The Journal of Infectious Diseases 182 (1): 274–282. doi:10.1086/315643. ISSN 0022-1899. PMID 10882607.

[18] "Untitled Document". www.fungisome.com. Retrieved 2015-11-03.

[19] "Drugs@FDA: FDA Approved Drug Products". www.accessdata.fda.gov. Retrieved 2015-11-03.

[20] "Drugs@FDA: FDA Approved Drug Products". www.accessdata.fda.gov. Retrieved 2015-11-03.

[21] Wasan KM, Wasan EK, Gershkovich P; et al. (2009). "Highly Effective oral amphotericin B formulation against murine visceral leishmaniasis". J Infect Dis 200 (3): 357–360. doi:10.1086/600105. PMID 19545212.

[22] Pappas, Peter G.; Kauffman, Carol A.; Andes, David; Benjamin, Daniel K.; Calandra, Thierry F.; Edwards, John E.; Filler, Scott G.; Fisher, John F.; Kullberg, Bart-Jan (2009-03-01). "Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America". Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 48 (5): 503–535. doi:10.1086/596757. ISSN 1537-6591. PMID 19191635.

[23] Patel, Pratikkumar A., and Vandana B. Patravale. "AmbiOnp: solid lipid nanoparticles of amphotericin B for oral administration." Journal of Biomedical Nanotechnology 7.5 (2011): 632-639.

[24] Wasan EK, Bartlett K, Gershkovich P, Sivak O, Banno B, Wong Z, Gagnon J, Gates B, Leon CG, Wasan KM. Development and characterization of oral lipid-based amphotericin B formulations with enhanced drug solubility, stability and antifungal activity in rats infected with Aspergillus fumigatus or Candida albicans. International Journal of Pharmaceutics. 2009; 372(1-2):76-84

[25] Patel PA, Patravale,VB. AmbiOnp: solid lipid nanoparticles of amphotericin B for oral administration. Journal of Biomedical Nanotechnology.2011; 7(5):632-639

[26] Italia JL, Yahya MM, Singh D. Biodegradable nanoparticles improve oral Bioavailability of Amphotericin B and Show Reduced Nephrotoxicity Compared to Intravenous Fungizone®. Pharmaceutical Research. 2009; 26 (6): 1324 -1331

[27] AL-Quadeib, Bushra T.; Radwan, Mahasen A.; Siller, Lidija; Horrocks, Benjamin; Wright, Matthew C. (2015-07-01). "Stealth Amphotericin B nanoparticles for oral drug delivery: In vitro optimization". Saudi Pharmaceutical Journal 23 (3): 290–302. doi:10.1016/j.jsps.2014.11.004. PMC 4475820. PMID 26106277.

[28] Patel PA, Fernandes CB, Pol AS, Patravale VB. Oral Amphotericin B: Challenges and avenues. Int. J. Pharm. Biosci. Technol. 2013;1(1):1–9

[29] MedBullets.Org - Amphotericin B

[30] Walsh, Thomas J.; Finberg, Robert W.; Arndt, Carola; Hiemenz, John; Schwartz, Cindy; Bodensteiner, David; Pappas, Peter; Seibel, Nita; Greenberg, Richard N. (1999-03-11). "Liposomal Amphotericin B for Empirical Therapy in Patients with Persistent Fever and Neutropenia". New England Journal of Medicine 340 (10): 764–771. doi:10.1056/NEJM199903113401004. ISSN 0028-4793. PMID 10072411.

[31] Perfect, John R.; Dismukes, William E.; Dromer, Francoise; Goldman, David L.; Graybill, John R.; Hamill, Richard J.; Harrison, Thomas S.; Larsen, Robert A.; Lortholary, Olivier (2010-02-01). "Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America". Clinical Infectious Diseases 50 (3): 291–322. doi:10.1086/649858. ISSN 1058-4838. PMID 20047480.

[32] Jill Adler-Moore,* and Richard T. liposomal formulation, structure, mechanism of action and pre-clinical experience. Journal of Antimicrobial Chemotherapy (2002) 49, 21–30

[33] J. Czub, M. Baginski. Amphotericin B and Its New Derivatives Mode of action. Department of pharmaceutical Technology and Biochemistry. Faculty of Chemistry, Gdnsk University of Technology. 2009, 10-459-469.

[34] Zietse, R.; Zoutendijk, R.; Hoorn, E. J. "Fluid, electrolyte and acid–base disorders associated with antibiotic therapy". Nature Reviews Nephrology 5 (4): 193–202. doi:10.1038/nrneph.2009.17.

[35] Angewandte Chemie Int. Ed. Engl. 2004^{[page needed]}

[Baginski2009-36] Baginski, M.; Czub, J. (2009). "Amphotericin B and Its New Derivatives–Mode of Action". Current Drug Metabolism 10 (5): 459–69. doi:10.2174/138920009788898019. PMID 19689243.

[:3-37] Mesa-Arango, Ana Cecilia; Scorzoni, Liliana; Zaragoza, Oscar (2012-01-01). "It only takes one to do many jobs: Amphotericin B as antifungal and immunomodulatory drug". Fungi and Their Interactions 3: 286. doi:10.3389/fmicb.2012.00286. PMC 3441194. PMID 23024638.

[38] O'Keeffe, Joseph; Doyle, Sean; Kavanagh, Kevin (2003-12-01). "Exposure of the yeast Candida albicans to the anti-neoplastic agent adriamycin increases the tolerance to amphotericin B". Journal of Pharmacy and Pharmacology 55 (12): 1629–1633. doi:10.1211/0022357022359. ISSN 2042-7158.

[:7-39] Dutcher, James D. (1968-10-01). "THe discovery and development of amphotericin b". Chest 54 (Supplement_1): 296–298. doi:10.1378/chest.54.Supplement_1.296. ISSN 0012-3692.

[Laniado-Laborin_R_2009-40] Laniado-Laborin R. and Cabrales-Vargas MN. Amphotericin B: side effects and toxicity. Revista Iberoamericana de Micologia. (2009): 223–7.

[41] Pfizer. Amphocin. Accessed at http://www.pfizer.com/files/products/uspi_amphocin.pdf on Feb 18 2010.

[42] Drew, R. Pharmacology of amphotericin B. Uptodate. Sep 2009. Accessed at http://www.utdol.com/online/content/topic.do?topicKey=antibiot/4619&selectedTitle=2~150&source=search_result on Feb 18 2010.

[43] Khan N, Rawlings B, Caffrey P (2011-01-26). "A labile point in mutant amphotericin polyketide synthases". Biotechnol Lett. 33 (6): 1121–6. doi:10.1007/s10529-011-0538-3. PMID 21267757.

[44] McNamara, Carmel M.; Box, Stephen; Crawforth, James M.; Hickman, Benjamin S.; Norwood, Timothy J. (1998-01-01). "Biosynthesis of amphotericin B". Journal of the Chemical Society, Perkin Transactions 1: 83–88. doi:10.1039/A704545J. |access-date= requires |url= (help)

[45] Caffrey, Patrick; Lynch, Susan; Flood, Elizabeth; Finnan, Shirley; Oliynyk, Markiyan (2001). "Amphotericin biosynthesis in Streptomyces nodosus: deductions from analysis of polyketide synthase and late genes". Chemistry & biology 8 (7): 713–723. doi:10.1016/S1074-5521(01)00046-1. |access-date= requires |url= (help)

[46] McNamara, Carmel M.; Box, Stephen; Crawforth, James M.; Hickman, Benjamin S.; Norwood, Timothy J.; Rawlings, Bernard J. "Biosynthesis of amphotericin B". Journal of the Chemical Society, Perkin Transactions 1 (1): 83–88. doi:10.1039/a704545j.

[47] Nicolaou, K. C.; Daines, R. A.; Chakraborty, T. K.; Ogawa, Y. (1987-04-01). "Total synthesis of amphotericin B". Journal of the American Chemical Society 109 (9): 2821–2822. doi:10.1021/ja00243a043. ISSN 0002-7863.

リンク元	「ambisome」
関連記事	「B」「amphotericin」「liposomal」「amphoteric」

匿名

検索

案内

案内

liposomal amphotericin B